GlaxoSmithKline plc (GSK) Insider Sells £262,000 in Stock
GlaxoSmithKline plc (LON:GSK) insider Patrick Vallance sold 20,000 shares of the company’s stock in a transaction that occurred on Monday, December 18th. The stock was sold at an average price of GBX 1,310 ($17.63), for a total value of £262,000 ($352,624.50).
Patrick Vallance also recently made the following trade(s):
- On Thursday, November 9th, Patrick Vallance purchased 10 shares of GlaxoSmithKline stock. The stock was bought at an average price of GBX 1,364 ($18.36) per share, with a total value of £136.40 ($183.58).
GlaxoSmithKline plc (LON:GSK) opened at GBX 1,310 ($17.63) on Thursday. GlaxoSmithKline plc has a 52-week low of GBX 1,270 ($17.09) and a 52-week high of GBX 1,724.50 ($23.21).
The company also recently declared a dividend, which will be paid on Thursday, January 11th. Investors of record on Thursday, November 9th will be given a dividend of GBX 19 ($0.26) per share. This represents a dividend yield of 1.41%. The ex-dividend date of this dividend is Thursday, November 9th.
A number of research firms have weighed in on GSK. UBS set a GBX 1,550 ($20.86) price target on GlaxoSmithKline and gave the stock a “buy” rating in a report on Wednesday, December 13th. Investec cut GlaxoSmithKline to a “hold” rating and decreased their price target for the stock from GBX 1,800 ($24.23) to GBX 1,390 ($18.71) in a report on Monday, November 6th. Citigroup restated a “neutral” rating and issued a GBX 1,400 ($18.84) price target on shares of GlaxoSmithKline in a report on Wednesday, December 13th. Berenberg Bank restated a “buy” rating and issued a GBX 1,760 ($23.69) price target on shares of GlaxoSmithKline in a report on Wednesday, December 13th. Finally, J P Morgan Chase & Co restated a “neutral” rating on shares of GlaxoSmithKline in a report on Thursday, September 21st. Three research analysts have rated the stock with a sell rating, eleven have issued a hold rating and eight have assigned a buy rating to the company’s stock. GlaxoSmithKline currently has a consensus rating of “Hold” and an average price target of GBX 1,562.86 ($21.03).
GlaxoSmithKline Company Profile
GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.